An experimental Moderna combination vaccine for influenza and Covid-19 showed in a pivotal study that it can elicit a higher immune response compared to vaccines that are already available to protect against infection from both viruses.

The post Moderna’s Flu & Covid-19 Combination Vaccine Succeeds in Phase 3 Clinical Trial appeared first on MedCity News.

GSK and Vir Biotechnology have ended their influenza collaboration, a move that follows last year’s Phase 2 failure for one of the partnered programs. Vir is now free to continue its flu research on its own, but the company says it’s actively pursuing other partners.

The post GSK and Vir Terminate Influenza Alliance a Year After Ending Covid-19 R&D Pact appeared first on MedCity News.

The FDA will decide this summer which strains the next Covid-19 vaccines should address. But companies are also taking a longer view, developing shots for the future that offer different features than the current ones and potentially broader protection against a wider range of pathogens.

The post The Public Health Emergency Is Expiring, So What Is the Future of Covid-19 Vaccines? appeared first on MedCity News.

Moderna’s mRNA vaccine for influenza has early data from a pivotal study showing it met trial goals assessing immune response against the more common strains of the virus, but missed against two less common types. A separate and ongoing Phase 3 study is assessing efficacy.

The post Moderna Flu Vax Prompts Response to More Common Strains, But Misses in Influenza B appeared first on MedCity News.

A webinar sponsored by BD scheduled for March 7 will explore how diagnostics companies are working with healthcare organizations to guard against the perfect storm of Covid-19, RSV and influenza. Register today!

The post How to Leverage Diagnostic Development to Guard Against RSV, Flu and Covid-19 appeared first on MedCity News.

GSK gave Vir Biotechnology a Valentine’s Day break-up message, but it’s not a complete goodbye. Though the two companies are ending their Covid-19 collaboration, they’ll still work together on other respiratory programs, including a prophylactic influenza antibody drug that is in mid-stage clinical development.

The post GSK’s Covid-19 Valentine to Vir Biotech: ‘You Can Go Your Own Way’ appeared first on MedCity News.

Xofluza, a flu antiviral drug developed by Roche and Shionogi, is now approved in Europe for children age 1 and older. The European Commission decision expands the patient population for the drug, which was previously approved for treating adolescents and adults.

The post Roche Influenza Antiviral Gets European Commission Approval for Young Kids appeared first on MedCity News.

Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.

The post Following Janssen flu deal, Leyden Labs gets $140M led by Casdin Capital and GV appeared first on MedCity News.

Diagnostics startup GRIP Molecular is developing an at-home test for Covid-19 and other respiratory infections. The technology builds on advances from several fields, including the discovery of graphene, a material that offers biocompatibility and conductivity.

The post GRIP Molecular goes with graphene to put powerful diagnostics into patient hands appeared first on MedCity News.

The amended pact follows a collaboration begun last year when GlaxoSmithKline paid Vir Biotechnology $250 million to team up on potential treatments for Covid-19. The expansion includes an influenza treatment based on Vir’s antibody technology.

The post GSK commits $345M to Vir as alliance expands to flu, other respiratory viruses appeared first on MedCity News.

Scripps Research launched a new study to see if data collective from wearable devices could be used to track flu-like illnesses, including Covid-19. In January, Scripps published a retrospective study using a similar methodology showing that sleep and resting heart rate data from Fitbits were correlated with the number of patients reporting influenza-like illness.  

The post Scripps researchers tap wearable data to track Covid-19 and flu appeared first on MedCity News.

A new study by the Scripps Research Translational Institute suggests Fitbits could be used to detect the flu. By tracking resting heart rate and activity levels, researchers said Fitbits could improve detection of outbreaks at the state level.

The post Scripps study: Can your Fitbit track the flu? appeared first on MedCity News.

Gilead is in-licensing investigational molecules for influenza, rhinovirus and herpes. Novartis will receive an upfront payment and an additional $291 million in milestones.

The post Gilead in-licenses drugs for respiratory, sexually transmitted infections from Novartis appeared first on MedCity News.

EHRs can be a nuisance. But new research shows data from electronic health records can be a useful tool for population health surveillance.

The post How can EHRs be used for population health purposes? appeared first on MedCity News.

The system’s estimates of national and regional flu activity had error rates 2- to 3-fold lower than earlier predictive models. It also correctly estimated the timing and magnitude of the national flu peak week.

The post EMR data helps Boston Children’s predict flu cases in real time appeared first on MedCity News.

The post Takeda backs antiviral maker Prosetta Biosciences in $31M round appeared first on MedCity News.

The post VaxInnate keeps slowly raising capital for seasonal flu vaccine appeared first on MedCity News.

The post Roche’s real-time tests for influenza A & B approved for point-of-care appeared first on MedCity News.

The post FluGen raises $12M Series A for “universal” flu vaccine appeared first on MedCity News.

The post New influenza vaccine fights the virus by not targeting it appeared first on MedCity News.

The post Well-capitalized VaxInnate gets another $6M for its bacteria-based flu vaccines appeared first on MedCity News.

The post Visterra bringing influenza immunotherapy into Phase 2 with $30M cash influx appeared first on MedCity News.

The post How Fujifilm played a role in the fight against Ebola appeared first on MedCity News.

The post Smart thermometer is the favorite at Cleveland Clinic & StartUp Health’s venture challenge appeared first on MedCity News.

The post Flu shot as Batman: Healthcare marketing hit or miss? appeared first on MedCity News.

The post Wow of the Week: 17-year-old Google Science Fair champ discovers new leads for anti-flu drugs appeared first on MedCity News.

The post Wow of the Week: A flu vaccination you could give yourself, with no shots involved appeared first on MedCity News.

The post Seattle biotech ups series B again to ID & develop antibodies as infectious disease therapies appeared first on MedCity News.

The post The latest innovation in flu meds: Startup using nanotech raises $6M appeared first on MedCity News.

The post If data is all the rage, why is it missing from the mandatory flu shot debate? appeared first on MedCity News.